Cargando…

Efficacy of mandibular advancement device in the treatment of obstructive sleep apnea syndrome: A randomized controlled crossover clinical trial

BACKGROUND: Evaluation of the efficacy and safety of a mandibular advancement device (MAD) (KlearwayTM) in the treatment of mild-to-moderate obstructive sleep apnea and chronic roncopathy. MATERIAL AND METHODS: A randomized, placebo-controlled, double blinded, and crossover clinical trial was conduc...

Descripción completa

Detalles Bibliográficos
Autores principales: Durán-Cantolla, Joaquín, Crovetto-Martínez, Rafael, Alkhraisat, Mohammad-Hamdan, Crovetto, Miguel, Municio, Antonio, Kutz, Ramón, Aizpuru, Felipe, Miranda, Erika, Anitua, Eduardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medicina Oral S.L. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598931/
https://www.ncbi.nlm.nih.gov/pubmed/26241460
http://dx.doi.org/10.4317/medoral.20649
_version_ 1782394159401795584
author Durán-Cantolla, Joaquín
Crovetto-Martínez, Rafael
Alkhraisat, Mohammad-Hamdan
Crovetto, Miguel
Municio, Antonio
Kutz, Ramón
Aizpuru, Felipe
Miranda, Erika
Anitua, Eduardo
author_facet Durán-Cantolla, Joaquín
Crovetto-Martínez, Rafael
Alkhraisat, Mohammad-Hamdan
Crovetto, Miguel
Municio, Antonio
Kutz, Ramón
Aizpuru, Felipe
Miranda, Erika
Anitua, Eduardo
author_sort Durán-Cantolla, Joaquín
collection PubMed
description BACKGROUND: Evaluation of the efficacy and safety of a mandibular advancement device (MAD) (KlearwayTM) in the treatment of mild-to-moderate obstructive sleep apnea and chronic roncopathy. MATERIAL AND METHODS: A randomized, placebo-controlled, double blinded, and crossover clinical trial was conducted. Placebo device (PD) defined as a splint in the centric occlusion that did not induce a mandibular advancement served as a control. The mandible was advanced to the maximum tolerable distance or to a minimum of 65% of the maximum protrusion. After each sequence of treatment, patients were assessed by questionnaires, conventional polysomnography, and objective measurement of snoring at the patient’s own home. RESULTS: Forty two patients participated in the study and 38 completed the study. Patients mean age was 46 ±9 years and the 79% were males. The mean mandibular advancement was 8.6 ±2.8 mm. Patients used the MAD and the PD for 6.4 +2.4 hours and 6.2 +2.0 hours, respectively. Secondary effects (mostly mild) occurred in the 85.7% and the 86.8% of the users of MAD and PD, respectively. The MAD induced a decrease in the apnea-hypopnea index (AHI) from 15.3 +10.2 to 11.9 +15.5. The 50% reduction in the AHI was achieved in the 46.2% and the 18.4% of the patients treated with MAD and PD, respectively. The use of the MAD induced a reduction in the AHI by 3.4 +15.9 while the PD induced an increase by 10.6 +26.1. The subjective evaluation of the roncopathy indicated an improvement by the MAD and an increase in the perceptive quality of sleep. However, the objective evaluation of the roncopathy did not show significant improvements. CONCLUSIONS: The use of MAD is efficient to reduce the AHI and improve subjectively the roncopathy. MAD could be considered in the treatment of mild-to-moderate OSA and chronic roncopathy. Key words:Obstructive sleep apnea (OSA), mandibular advance device, treatment, efficacy, clinical assay.
format Online
Article
Text
id pubmed-4598931
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medicina Oral S.L.
record_format MEDLINE/PubMed
spelling pubmed-45989312015-10-15 Efficacy of mandibular advancement device in the treatment of obstructive sleep apnea syndrome: A randomized controlled crossover clinical trial Durán-Cantolla, Joaquín Crovetto-Martínez, Rafael Alkhraisat, Mohammad-Hamdan Crovetto, Miguel Municio, Antonio Kutz, Ramón Aizpuru, Felipe Miranda, Erika Anitua, Eduardo Med Oral Patol Oral Cir Bucal Research BACKGROUND: Evaluation of the efficacy and safety of a mandibular advancement device (MAD) (KlearwayTM) in the treatment of mild-to-moderate obstructive sleep apnea and chronic roncopathy. MATERIAL AND METHODS: A randomized, placebo-controlled, double blinded, and crossover clinical trial was conducted. Placebo device (PD) defined as a splint in the centric occlusion that did not induce a mandibular advancement served as a control. The mandible was advanced to the maximum tolerable distance or to a minimum of 65% of the maximum protrusion. After each sequence of treatment, patients were assessed by questionnaires, conventional polysomnography, and objective measurement of snoring at the patient’s own home. RESULTS: Forty two patients participated in the study and 38 completed the study. Patients mean age was 46 ±9 years and the 79% were males. The mean mandibular advancement was 8.6 ±2.8 mm. Patients used the MAD and the PD for 6.4 +2.4 hours and 6.2 +2.0 hours, respectively. Secondary effects (mostly mild) occurred in the 85.7% and the 86.8% of the users of MAD and PD, respectively. The MAD induced a decrease in the apnea-hypopnea index (AHI) from 15.3 +10.2 to 11.9 +15.5. The 50% reduction in the AHI was achieved in the 46.2% and the 18.4% of the patients treated with MAD and PD, respectively. The use of the MAD induced a reduction in the AHI by 3.4 +15.9 while the PD induced an increase by 10.6 +26.1. The subjective evaluation of the roncopathy indicated an improvement by the MAD and an increase in the perceptive quality of sleep. However, the objective evaluation of the roncopathy did not show significant improvements. CONCLUSIONS: The use of MAD is efficient to reduce the AHI and improve subjectively the roncopathy. MAD could be considered in the treatment of mild-to-moderate OSA and chronic roncopathy. Key words:Obstructive sleep apnea (OSA), mandibular advance device, treatment, efficacy, clinical assay. Medicina Oral S.L. 2015-09 2015-08-04 /pmc/articles/PMC4598931/ /pubmed/26241460 http://dx.doi.org/10.4317/medoral.20649 Text en Copyright: © 2015 Medicina Oral S.L. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Durán-Cantolla, Joaquín
Crovetto-Martínez, Rafael
Alkhraisat, Mohammad-Hamdan
Crovetto, Miguel
Municio, Antonio
Kutz, Ramón
Aizpuru, Felipe
Miranda, Erika
Anitua, Eduardo
Efficacy of mandibular advancement device in the treatment of obstructive sleep apnea syndrome: A randomized controlled crossover clinical trial
title Efficacy of mandibular advancement device in the treatment of obstructive sleep apnea syndrome: A randomized controlled crossover clinical trial
title_full Efficacy of mandibular advancement device in the treatment of obstructive sleep apnea syndrome: A randomized controlled crossover clinical trial
title_fullStr Efficacy of mandibular advancement device in the treatment of obstructive sleep apnea syndrome: A randomized controlled crossover clinical trial
title_full_unstemmed Efficacy of mandibular advancement device in the treatment of obstructive sleep apnea syndrome: A randomized controlled crossover clinical trial
title_short Efficacy of mandibular advancement device in the treatment of obstructive sleep apnea syndrome: A randomized controlled crossover clinical trial
title_sort efficacy of mandibular advancement device in the treatment of obstructive sleep apnea syndrome: a randomized controlled crossover clinical trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598931/
https://www.ncbi.nlm.nih.gov/pubmed/26241460
http://dx.doi.org/10.4317/medoral.20649
work_keys_str_mv AT durancantollajoaquin efficacyofmandibularadvancementdeviceinthetreatmentofobstructivesleepapneasyndromearandomizedcontrolledcrossoverclinicaltrial
AT crovettomartinezrafael efficacyofmandibularadvancementdeviceinthetreatmentofobstructivesleepapneasyndromearandomizedcontrolledcrossoverclinicaltrial
AT alkhraisatmohammadhamdan efficacyofmandibularadvancementdeviceinthetreatmentofobstructivesleepapneasyndromearandomizedcontrolledcrossoverclinicaltrial
AT crovettomiguel efficacyofmandibularadvancementdeviceinthetreatmentofobstructivesleepapneasyndromearandomizedcontrolledcrossoverclinicaltrial
AT municioantonio efficacyofmandibularadvancementdeviceinthetreatmentofobstructivesleepapneasyndromearandomizedcontrolledcrossoverclinicaltrial
AT kutzramon efficacyofmandibularadvancementdeviceinthetreatmentofobstructivesleepapneasyndromearandomizedcontrolledcrossoverclinicaltrial
AT aizpurufelipe efficacyofmandibularadvancementdeviceinthetreatmentofobstructivesleepapneasyndromearandomizedcontrolledcrossoverclinicaltrial
AT mirandaerika efficacyofmandibularadvancementdeviceinthetreatmentofobstructivesleepapneasyndromearandomizedcontrolledcrossoverclinicaltrial
AT anituaeduardo efficacyofmandibularadvancementdeviceinthetreatmentofobstructivesleepapneasyndromearandomizedcontrolledcrossoverclinicaltrial